Genentech Polivy’s Benefit-Risk Profile In First-Line Lymphoma Under Scrutiny

 
• By Sue Sutter
  
First step
Genentech is seeking to make Polivy an option in the first-line setting. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers